Zentiva: Growing into a regional pharmaceutical powerhouse
By 2021, Zentiva relied on an internationally diversified network of manufacturing sites, ensuring the production and supply of medicines to millions of people in Europe and beyond. Employing more than 2,300 employees in its wholly owned sites, primarily in Eastern Europe, Zentiva produced medicines that were sold in more than 40 countries. Against the backdrop of changes in the pharma industry – particularly in Europe and in the leading generics market players, which were focused on gaining scale to reduce manufacturing and distribution costs – Zentiva had bold ambitions to become a leading generics and over-the-counter (OTC) manufacturer in Europe by 2025. How could Zentiva derive the benefits of the transformational trends that were impacting pharma players around the world? In view of the changes characterizing the European landscape, would an almost exclusive focus on Eastern Europe be the optimal international growth strategy for the company going forward?
- Analyze the extent to which the pharmaceutical industry is transforming itself and how this is creating new opportunities and challenges for incumbents such as Zentiva
- Analyze the extent to which international expansion can be instrumental in Zentiva’s growth and success in the marketplace
- Explore how companies such as Zentiva can create value via their international footprint
- Explore strategy in an environment characterized by a high degree of uncertainty
Zentiva, Healthcare, Pharmaceuticals
2019-2022
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
- Ducati: Adding value abroad in a post-pandemic world?
- Kellogg: Localizing foreign entry mode
- Tesla’s global expansion: Where to go next?
- Zentiva: Growing into a regional pharmaceutical powerhouse
- Ducati: Adding value abroad in a post-pandemic world?
- Kellogg: Localizing foreign entry mode
- Tesla’s global expansion: Where to go next?
- Zentiva: Growing into a regional pharmaceutical powerhouse
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
![](https://www.imd.org/ibyimd/wp-content/uploads/2023/10/AdobeStock_466698922-1-720x630.jpeg)
Understanding your organizational capacity for agility and responding to events accordingly is the key to success in the new business environment, ...
![](https://www.imd.org/ibyimd/wp-content/uploads/2024/06/AdobeStock_279581139-720x630.jpeg)
In a post-pandemic era shaped by wars, climate change, and new technologies, Maha Hosain Aziz outlines the main risks and shock events that could d...
The case study examines recent aviation safety concerns at Boeing, focusing on manufacturing issues, leadership decisions and regulatory oversight....
![](https://www.imd.org/ibyimd/wp-content/uploads/2024/06/CEODialogue-MargheritaDellaValle-IbyIMD-LandingPage-Podcast-1200x680-1-720x630.jpg)
Margherita Della Valle tells IMD President Jean-François Manzoni how she is delivering radical change to reenergize Vodafone and paving the way for...
The case is seen through the eyes of the newly appointed supply chain director at a cosmetics company based in Berlin. The general manager has task...
Few Business to Business (B2B) marketplaces have succeeded. Metalshub has successfully combined a software platform as a service, with a marketplac...
The case focuses on Contabilizei, a Brazilian startup providing online accounting services for small and medium-sized enterprises (SMEs). The case ...
![](https://www.imd.org/ibyimd/wp-content/uploads/2024/05/General-image-banner-16-720x630.jpg)
IMD's Niccolò Pisani examines how a combination of clear-eyed analysis and a strong sense of purpose allowed the French biopharma to change course.
Companies that modularize and externalize their best capabilities are in a strong position to seize unexpected opportunities. Prediction is hard. T...
![](https://www.imd.org/ibyimd/wp-content/uploads/2024/06/UEFA-Featured-720x630.jpg)
Leading Chinese companies are preparing to take advantage of exposure and opportunities as top sponsors and suppliers to the UEFA EURO 2024 Men’s S...
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD 24 June 2024
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-7-2457 ©2024
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-7-2546 ©2024
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in MIT Sloan Management Review Summer 2024, vol. 65, no. 4
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications